drugset / Trial / NCT02026973
Impact of Endogenous E2 on SSI and GH Rebound
RandomizedCrossoverTriple-blindBasic science
Summary
Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 2 mg | Oral |
| Subject | Fulvestrant | Small molecule | 250 mg | Intramuscular |
| Subject | Somatostatin | Traditional medicine (herbal / TCM) | 1 ug/kg | — |
Indications
No indication recorded.